MedTrace Logo

A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)

NCT00131404 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2400

Last updated 2015-02-05

No results posted yet for this study

Summary

A study to determine the safety and efficacy of an investigational drug in patients with obesity plus extension.

Conditions

Interventions

DRUG

taranabant

taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.

DRUG

Comparator: Placebo

Placebo capsule once daily. 52 week treatment period.

Sponsors & Collaborators

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-02-28
Completion
2008-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00131404 on ClinicalTrials.gov